Lange explained on a conference call that one reason for the miss was a flexible treatment protocol that allowed patients to ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

In the last reported quarter, the company delivered a negative earnings surprise of 22.37%, as seen in the chart below ... and weight loss medicine, Zepbound. However, in mid-January, Lilly ...

Eli Lilly and Company LLY will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.

The study enrolled 125 overweight or obese patients, with some receiving different doses of the drug ... impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs.

“It never occurred to me to ask, Well, what does this mean for us?” Jeanne took her first dose of Zepbound on March 7, 2024. Since then, she has lost 60 pounds; a recent liver scan showed no ...

One Eli Lilly-backed trial showed that Zepbound was better than Wegovy at ... only 57.3% of patients took the full dose throughout the trial period, with other participants opting to lower their ...